Ultrasound appearance of the uterus in women over 60 years of age on tibolone: is it a SERM?

References

• Hanggi W, Bersinger N, Altermatt H J, Birkhauser M H. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas 1997; 27: 133–143
   PubMed Web of Science ®Google Scholar
• Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998; 30: 295–305
   PubMed Web of Science ®Google Scholar
• Wender M C, Edelweiss M I, Campos L S, de Castro J A, Spritzer P M. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 2004; 11: 423–429
   PubMed Web of Science ®Google Scholar
• Botsis D, Kassanos D, Kalogirou D, Antoniou G, Vitoratos N, Karakitsos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. Maturitas 1997; 26: 57–62
   PubMed Web of Science ®Google Scholar
• Doren M, Rubig A, Coelingh Bennink H J, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6: 299–306
   PubMed Web of Science ®Google Scholar
• Volker W, Coelingh Bennink H J, Helmond F A. Effects of tibolone on the endometrium. Climacteric 2001; 4: 203–208
   PubMedGoogle Scholar
• Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–1551
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004; 48: 30–40
   PubMed Web of Science ®Google Scholar
• Kloosterboer H J, Ederveen A G. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/−progestogen) treatments. J Steroid Biochem Mol Biol 2002; 83: 157–165
   PubMed Web of Science ®Google Scholar
• Bese T, Kösebay D, Demirkiran F, Arvas M, Bese N, Mandel N. Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen. Eur J Obstet Gynecol Reprod Biol 1996; 67: 157–162
   PubMed Web of Science ®Google Scholar
• Bornstein J, Auslender R, Pascal B, Gutterman E, Isakov D, Abramovici H. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 1994; 39: 674–678
   PubMed Web of Science ®Google Scholar
• Goldstein S R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447–451
   PubMed Web of Science ®Google Scholar
• Achiron R, Lipitz S, Sivan E, Goldenberg M, Mashiach S. Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 1995; 14: 685–688
   PubMed Web of Science ®Google Scholar
• Perez-Medina T, Bajo-Arenas J, Haya J, et al. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause 2003; 10: 534–537
   PubMed Web of Science ®Google Scholar
• Achiron R, Grisaru D, Golan-Porat, Lipitz S. Tamoxifen and the uterus: an old drug tested by new modalities. Ultrasound Obstet Gynecol 1996; 7: 374–378
   PubMed Web of Science ®Google Scholar
• Martino S, Disch D, Dowsett S A, Keech C A, Mershon J L. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005; 21: 1441–1452
   PubMed Web of Science ®Google Scholar
• Neven P, Quail D, Marin F, Creatsas G, et al. Comparing raloxifene with continuous combined estrogen–progestin therapy in postmenopausal women: Review of Euralox 1. Maturitas 2005; 52: 87–101
   PubMed Web of Science ®Google Scholar
• Lindahl B, Andolf E, Ingvar C, Liedman R, Ranstam J, Willen R. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Res 1997; 17: 3821–3824
   PubMed Web of Science ®Google Scholar
• Marttunen M B, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001; 84: 897–902
   PubMed Web of Science ®Google Scholar
• Henke B R, Heyer D. Recent advances in estrogen receptor modulators. Curr Opin Drug Discov Devel 2005; 8: 437–448
   PubMed Web of Science ®Google Scholar
• Gielen S C, Burger C W, Kuhne L C, Hanifi-Moghaddam P, Blok L J. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig 2005; 12: e55–e67
   PubMedGoogle Scholar
• De Vries C S, Bromley S E, Thomas H, Farmer R D. Tibolone and endometrial cancer: a cohort and nested case–control study in the UK. Drug Saf 2005; 28: 241–249
   PubMed Web of Science ®Google Scholar